Positive results of Agenus anti-PD-1 monoclonal antibody for treatment of refractory cervical cancer stage 2

On August 26, 2021, Agenus announced that its anti-PD-1 monoclonal antibody batilimumab (balstilimab), a single-drug treatment of recurrent/metastatic cervical cancer, was published online in the international peer-reviewed journal.
Gynecologic Oncology
.

Batilizumab is a fully human monoclonal immunoglobulin G4 (IgG4) antibody, designed to target and inhibit the interaction of PD-1 and its ligands PD-L1 and PD-L2 to activate the immune system to attack tumors
.

In this open-label, single-arm global phase 2 clinical trial, the trial results showed that among 140 evaluable patients, the objective response rate (ORR) of PD-L1 positive tumor patients was 20.
0%, including 3 cases Patients (3/85, 3.
5%) had complete remission, and 14 patients (14/85, 16.
5%) showed partial remission
.

The ORR of confirmed PD-L1 positive or negative tumor patients was 15.
0%, including 5 patients (3.
6%) with complete remission and 16 patients (11.
4%) with partial remission
.

It is worth noting that the drug has been observed to respond in all histological subgroups of cervical cancer, including patients who did not respond to other therapies
.

Reference materials:

[1] Balstilimab Monotherapy Data Published in Gynecologic Oncology.

(The original text has been deleted)